Cardionovum

Be up
to date.

Latest press release

CARDIONOVUM GmbH today announced the completion of enrollment of the RAPID trial. Results will be used to further support the safety and effectiveness of CARDIONOVUM’s Legflow® drug-coated balloon (DCB).

CARDIONOVUM GmbH, a medical technology company developing and commercializing innovative medical devices such as drug-coated balloons and drug-eluting stents for the treatment of coronary and peripheral artery disease, announced today the enrollment of the first patient in the MAGNIFICENT trial.

Cardionovum experiences increase in demand for its innovative, and next generation „RESTORE Paclitaxel-releasing coronary balloon dilatation catheter.“ The American Journal of Cardiology, issue December 2015, published study results on the efficacy and safety of Paclitaxel coated balloon catheters for the treatment of in-stent restenosis in high risk patients. The RESTORE DEB showed significant superiority with lowest incidence of restenosis, if compared to other contemporary coronary DEBs.

Dr. Jean Paul de Vries (PI) presented the patient study results of the multi-center randomized RAPID trial.

Cardionovum prepares for a first international publication on 6-12 months FU patient results from the ongoing APERTO clinical study program. The APERTO Paclitaxel-releasing high pressure shunt balloon dilatation catheter was exclusively designed to treat shunt stenosis of hemodialysis patients.

Upcoming events

Currently there are no events.

Latest events

Cardionovum at LINC

Cardionovum participates at LINC Leipzig Interventional Course

Date: Jan 24, 2017–Jan 27, 2017

Location: Leipzig, Germany

Learn more >>

Visit website >>

Cardionovum at CIRSE

Cardionovum participates at CIRSE

Date: Sep 09, 2016–Sep 13, 2016

Location: Barcelona, Spain

Visit website >>

Cardionovum at EuroPCR

Cardionovum participates at EuroPCR

Date: May 16, 2016–May 19, 2016

Location: Paris, France

Visit website >>

go top